NCT00399802View on ClinicalTrials.gov

A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED)

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 16, 2006

Primary Completion Date

December 5, 2007

Study Completion Date

December 5, 2007

Conditions
Breast CancerMetastatic Bone Disease
Interventions
DRUG

ZA

Single ZA 4 mg IV infusion at the start of treatment

DRUG

Odanacatib

Once-daily odanacatib 5 mg tablet for 4 weeks

DRUG

Odanacatib matching placebo

Once-daily odanacatib matching placebo for 4 weeks

DRUG

ZA matching placebo

Single IV infusion of ZA matching placebo given at the start of treatment

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00399802 - A Study to Examine the Effects of an Experimental Drug on Women With Breast Cancer and Metastatic Bone Disease (MBD)(0822-016)(COMPLETED) | Biotech Hunter | Biotech Hunter